According to @ChildrensHD, the U.S. FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) convened to discuss and recommend the COVID-19 vaccine formula for 2025-2026. While public concerns were raised regarding vaccine safety, official VRBPAC documentation and meeting notes confirm the session focused on efficacy and variant coverage (FDA.gov, 2025-05-22). There is no FDA acknowledgement of adverse effects beyond established side effect profiles. This regulatory decision may impact biotech stock volatility, particularly for companies involved in mRNA technology. Crypto traders should monitor related biotech equities and broader risk sentiment, as regulatory news has previously driven sector rotation and correlated crypto market moves during similar health sector events (Cointelegraph, 2023-07-17).